Galapagos N.V. Total Liabilities
Galapagos N.V. total liabilities. Based on the latest financial reports, Galapagos N.V. (GLPG) has total liabilities worth €119.06 Million EUR (≈ $139.19 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Galapagos N.V. (GLPG) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Galapagos N.V. (2004–2025)
Total liabilities of Galapagos N.V. from 2004 to 2025. This chart illustrates how Galapagos N.V.'s total liabilities have evolved over time, based on quarterly financial data. Explore Galapagos N.V. (GLPG) investment intensity to see how much of total assets are deployed in long-term investments.
Galapagos N.V. Competitors by Total Liabilities
The table below lists competitors of Galapagos N.V. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Metrovacesa SA
MC:MVC
|
Spain | €843.82 Million |
|
Devyani International Limited
NSE:DEVYANI
|
India | Rs-18.85 Billion |
|
Vardhman Textiles Limited
NSE:VTL
|
India | Rs-105.88 Billion |
|
Telkom
JSE:TKG
|
South Africa | ZAC28.53 Billion |
|
China Railway Construction Corporation Limited
F:4FF
|
Germany | €1.70 Trillion |
|
Corporativo GBM S.A.B. de C.V
MX:GBMO
|
Mexico | MX$65.10 Billion |
|
Friedrich Vorwerk Group SE
F:VH2
|
Germany | €210.59 Million |
|
Century Plyboards (India) Limited
NSE:CENTURYPLY
|
India | Rs27.56 Billion |
Liability Composition Analysis (2004–2025)
This chart breaks down Galapagos N.V.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Galapagos N.V. assets under control.
Liquidity & Leverage Metrics
Galapagos N.V. Total Liabilities Ratios Explained
Galapagos N.V. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 30.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Galapagos N.V.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Galapagos N.V. (2004–2025)
The table below shows the annual total liabilities of Galapagos N.V. from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €170.65 Million ≈ $199.51 Million |
-86.22% |
| 2024-12-31 | €1.24 Billion ≈ $1.45 Billion |
-20.68% |
| 2023-12-31 | €1.56 Billion ≈ $1.83 Billion |
-29.28% |
| 2022-12-31 | €2.21 Billion ≈ $2.58 Billion |
-13.39% |
| 2021-12-31 | €2.55 Billion ≈ $2.98 Billion |
-16.33% |
| 2020-12-31 | €3.05 Billion ≈ $3.56 Billion |
-4.56% |
| 2019-12-31 | €3.19 Billion ≈ $3.73 Billion |
+1317.53% |
| 2018-12-31 | €225.25 Million ≈ $263.34 Million |
-17.88% |
| 2017-12-31 | €274.29 Million ≈ $320.68 Million |
-15.51% |
| 2016-12-31 | €324.64 Million ≈ $379.53 Million |
+318.81% |
| 2015-12-31 | €77.52 Million ≈ $90.62 Million |
+20.49% |
| 2014-12-31 | €64.33 Million ≈ $75.21 Million |
-46.50% |
| 2013-12-31 | €120.24 Million ≈ $140.57 Million |
+2.87% |
| 2012-12-31 | €116.88 Million ≈ $136.65 Million |
+173.86% |
| 2011-12-31 | €42.68 Million ≈ $49.90 Million |
-6.11% |
| 2010-12-31 | €45.45 Million ≈ $53.14 Million |
+30.49% |
| 2009-12-31 | €34.83 Million ≈ $40.72 Million |
+0.96% |
| 2008-12-31 | €34.50 Million ≈ $40.33 Million |
-31.13% |
| 2007-12-31 | €50.10 Million ≈ $58.57 Million |
-13.78% |
| 2006-12-31 | €58.10 Million ≈ $67.93 Million |
+184.45% |
| 2005-12-31 | €20.43 Million ≈ $23.88 Million |
+289.38% |
| 2004-12-31 | €5.25 Million ≈ $6.13 Million |
-- |
About Galapagos N.V.
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory no… Read more